Quidelortho Corp
F:QL1A

Watchlist Manager
Quidelortho Corp Logo
Quidelortho Corp
F:QL1A
Watchlist
Price: 11.715 EUR -18.81% Market Closed
Market Cap: €784.6m

Quidelortho Corp
Total Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Quidelortho Corp
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Quidelortho Corp
F:QL1A
Total Liabilities
$3.8B
CAGR 3-Years
-1%
CAGR 5-Years
48%
CAGR 10-Years
35%
Boston Scientific Corp
NYSE:BSX
Total Liabilities
$19.4B
CAGR 3-Years
9%
CAGR 5-Years
5%
CAGR 10-Years
5%
Edwards Lifesciences Corp
NYSE:EW
Total Liabilities
$3.4B
CAGR 3-Years
11%
CAGR 5-Years
5%
CAGR 10-Years
8%
Stryker Corp
NYSE:SYK
Total Liabilities
$25.4B
CAGR 3-Years
8%
CAGR 5-Years
4%
CAGR 10-Years
13%
Abbott Laboratories
NYSE:ABT
Total Liabilities
$34.6B
CAGR 3-Years
-2%
CAGR 5-Years
-2%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Total Liabilities
$2.6B
CAGR 3-Years
11%
CAGR 5-Years
13%
CAGR 10-Years
16%
No Stocks Found

Quidelortho Corp
Glance View

Market Cap
784.6m EUR
Industry
Health Care

QuidelOrtho Corporation has emerged as a significant player in the realm of diagnostic healthcare, formed through the strategic merger of Quidel Corporation and Ortho Clinical Diagnostics. This union brought together Quidel's expertise in rapid diagnostic testing solutions and Ortho Clinical's strengths in in vitro diagnostics, aiming to create a powerhouse capable of addressing the evolving needs of modern healthcare systems globally. Quidel, originally known for its swift point-of-care diagnostic tools for infectious and other diseases, found a strategic complement in Ortho Clinical's laboratory-based testing and transfusion medicine capabilities. This merger allowed QuidelOrtho to leverage both companies’ technological innovations and established customer bases, effectively broadening their market reach and ensuring a diversified revenue stream. The company operates by developing, manufacturing, and marketing a comprehensive range of diagnostic solutions that serve both healthcare professionals and patients alike. At the heart of QuidelOrtho's operations is its commitment to enhancing patient outcomes through precision testing—a focus that aligns with the growing demand for accurate and reliable diagnostic information. Revenue generation stems from its extensive portfolio, which includes point-of-care testing kits, laboratory instruments, and other diagnostic equipment. By providing indispensable tools that aid in the early detection and management of diseases, QuidelOrtho not only supports healthcare providers in improving clinical outcomes but also positions itself as a crucial contributor to the global medical landscape. Its varied product lines and strategic innovations continue to reinforce its role in promoting public health and advancing medical diagnostics.

QL1A Intrinsic Value
44.845 EUR
Undervaluation 74%
Intrinsic Value
Price €11.715

See Also

What is Quidelortho Corp's Total Liabilities?
Total Liabilities
3.8B USD

Based on the financial report for Dec 28, 2025, Quidelortho Corp's Total Liabilities amounts to 3.8B USD.

What is Quidelortho Corp's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
35%

Over the last year, the Total Liabilities growth was 12%. The average annual Total Liabilities growth rates for Quidelortho Corp have been -1% over the past three years , 48% over the past five years , and 35% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett